MYCN/MYC-mediated drug resistance mechanisms in neuroblastoma

International Journal of Clinical Pharmacology and Therapeutics

Volumn 48, Issue 7, 2010, Pages 489-491

  Gogolin, S ^a   Dreidax, D ^a   Becker, G ^a   Ehemann, V ^a   Schwab, M ^a   Westermann, F ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

DNA damage response; Drug resistance; MDM2; MYCN c MYC; Neuroblastoma; Nutlin 3a

Indexed keywords

DNA; DOXORUBICIN; MYC PROTEIN; NUTLIN 3; ONCOPROTEIN; PROTEIN MDM2; PROTEIN MYCN; PROTEIN P53; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER RESISTANCE; CELL CYCLE ARREST; CONFERENCE PAPER; CONTROLLED STUDY; DNA DAMAGE; FLUORESCENCE ACTIVATED CELL SORTING; GENE AMPLIFICATION; NEUROBLASTOMA; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION;

EID: 77954904144     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP48489     Document Type: Conference Paper

References (7)

1. Bell E, Premkumar R, Carr J, Lu X, Lovat PE, Kees UR, Lunec J, Tweddle DA. The role of MYCN in the failure of MYCN amplified neuroblastoma cell lines to G1 arrest after DNA damage. Cell Cycle. 2006; 5: 2639-2647. (Pubitemid 44785808)
2. De Bernardi B, Nicolas B, Boni L, Indolfi P, Carli M, Cordero Di Montezemolo L, Donfrancesco A, Pession A, Provenzi M, di Cataldo A, Rizzo A, Tonini GP, Dallorso S, Conte M, Gambini C, Garaventa A, Bonetti F, Zanazzo A, D'Angelo P, Bruzzi P. Disseminated neuroblastoma in children older than one year at diagnosis: comparable results with three consecutive high-dose protocols adopted by the Italian Co-Operative Group for Neuroblastoma. J Clin Oncol. 2003; 21: 1592-1601. (Pubitemid 46594114)
3. Matthay KK, Villablanca JG, Seeger RC, Stram DO, Harris RE, Ramsay NK, Swift P, Shimada H, Black CT, Brodeur GM, Gerbing RB, Reynolds CP. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med. 1999; 341: 1165-1173. (Pubitemid 29480654)
4. Molenaar JJ, Ebus ME, Geerts D, Koster J, Lamers F, Valentijn LJ, Westerhout EM, Versteeg R, Caron HN. Inactivation of CDK2 is synthetically lethal to MYCN over-expressing cancer cells. Proc Natl Acad Sci U S A. 2009; 106: 12968-12973.
5. Oberthuer A, Theissen J, Westermann F, Hero B, Fischer M. Molecular characterization and classification of neuroblastoma. Future Oncol. 2009; 5: 625-639.
6. Westermann F, Muth D, Benner A, Bauer T, Henrich KO, Oberthuer A, Brors B, Beissbarth T, Vandesompele J, Pattyn F, Hero B, Konig R, Fischer M, Schwab M. Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas. Genome Biol. 2008; 9: 150.
7. Zage PE, Kletzel M, Murray K, Marcus R, Castleberry R, Zhang Y, London WB, Kretschmar C. Outcomes of the POG 9340/9341/9342 trials for children with high-risk neuroblastoma: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2008; 51: 747-753.